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Abstract
Null hypothesis significance testing dominates the current 
biostatistical practice. However, this routine has many flaws, 
in particular p-values are very often misused and misinter-
preted. Several solutions has been suggested to remedy this 
situation, the application of Bayes Factors being perhaps the 
most well-known. Nevertheless, even Bayes Factors are very 
seldom applied in medical research. This paper investigates 
the application of Bayes Factors in the analysis of a realistic 
medical problem using actual data from a representative US 
survey, and compares the results to those obtained with tra-
ditional means. Linear regression is used as an example as 
it is one of the most basic tools in biostatistics. The effect of 
sample size and sampling variation is investigated (with res-
ampling) as well as the impact of the choice of prior. Results 
show that there is a strong relationship between p-values and 
Bayes Factors, especially for large samples. The application 
of Bayes Factors should be encouraged evenin spite of this, as 
the message they convey is much more instructive and scientif-
ically correct than the current typical practice.
Keywords
Bayes Factor, p-value, null hypothesis significance testing, 
linear regression model
1 Introduction
The application of  p​-values​ –​ and​ null​ hypothesis​ signifi-
cance testing in general – remains a controversial topic in many 
applied​statistical​fields,​ including​biostatistics.​The​currently​
most​widely​used​(frequentist)​apparatus​of​biostatistics​does-
not – as readers, clinical researchers and sometimes even text-
books​ seem​ to​ believe​ –​ represent​ a​ straightforward​ logical​
construct,​ but​ rather​ an​ incompatible​ hybrid​ of​ the​Fisherian​
and​the​Neyman-Pearson​tradition​[1-4],​which​is​itself​prob-
lematic, and an application and interpretation routine that is 
often​deeply​flawed.​The​most​important​typical​errors,​falla-
cies, misunderstandings and misuses include [5-11]: 
•​ Confusing​clinical​significance​(whether​the​effect​size​is​
meaningful in the domain, in this case, medically) with 
statistical​significance​(whether​the​effect​is​assumed​to​be​
larger​than​what​can​be​attributed​to​sampling​variation).​
• Application of the apparatus in non-sampling situations 
or​for​extremely​large​samples.​
• Forgetting that p-values and the related inferential appa-
ratus​only​capture​sampling​error,​but​say​nothing​of​the​
potential​non-sampling​sources​of​error​(i.e.​biases).​
• Forgetting whether the null hypothesis is – medically – 
meaningful​at​all​or​not​(especially​point​nulls).​





These​ problems​ are​ so​ profound,​ despite​ that​ so​ preva-
lent​ [14],​ that​ there​ have​ been​ memorable​ attempts​ which​
implemented​ the​ most​ radical​ solution:​ banning​ the​ appara-
tus​ completely​ or​ almost​ completely.​ Perhaps​ most​ notable​
is​ the​case​of​ the​Epidemiology​ journal​ [15]​ (with​ the​ rather​
strict policy removed in 2001 when founding editor Kenneth 
Rothman stepped down [16]) and the more recent example of 
the​ journal​Basic​ and​Applied​ Social​ Psychology​ [17].These​
decisions, in particular the question whether they are effective 
or needed, led to a widespread controversy, with American 
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Statistical​Association​(ASA)​issuing​a​statement​in​mid-2016,​
formulating​ the​ views​ of​ the​world’s​ leading​ scientific​ body​
and​gathering​many​relevant​paper​in​the​topic​[18].​
The most important is perhaps the last fallacy from the 
above​ list:​many​readers​are​ tempted​ to​beleive​ that​p-values 






 P ( H 0​ | ) =  








simple situation, a  p​-value​of​​0.05​might​very​well​mean​36%​
probability​ that​ the​ null​ is​ true​ (no​ effect​ found)​ if​ the​ prior​
probability​is​only​10%​[19,​20].​(We​assumed​80%​power,​a​
typical​value.)​With​more​advanced​tools,​it​it​even​possible​to​
show that for  p​ =​ 0.05​ the​probability​of​ the​null​being​ true​
cannot be smaller​than​28.9%​no​matter​what​situation​we​pre-
sume​[21,​22].​
Many​attempts​have​been​made​ to​ replace​or​at​ least​ sup-









–​most​well-known.​The​basic​ idea​ is​ rather​ simple:​ take​ the​
same​equation​as​(1)​but​for​​H 1 (instead of  H 0 ), and divide the 
two;​thus​we​obtain​
 
P ( H 0​ | )  ______P ( H 1​ | ) 
 =  
P ( | ​H 0 )  ______P ( | ​H 1 ) 
 ⋅  
P ( H 0 )  _____P ( H 1 ) 
as the term  P ()​ fortunately​ cancels.​ Noting​ that​ ​P ( H 1 ) = 
1​−​P ( H 0 )​ (and​ likewise​ for​ the​ conditional​ probability)​ we​
actually have 
 
P ( H 0​ | )  ________ 1​−​P ( H 0​ | ) 
=  
P ( | ​H 0 )  ______P ( | ​H 1 ) 
 ⋅  
P ( H 0 )  ______ 1​−​P ( H 0 ) 
, 
but​a​probability​divided​by​one​minus​that​probability​is​odds,​
so we can write
 odds ( H 0​ | ) =  
P ( | ​H 0 )  ______P ( | ​H 1 ) 
 ⋅ odds ( H 0 )​.​
The remaining factor on the right-hand side is called Bayes 
Factor [23, 24]: 
 B  F 01 =  
P ( | ​H 0 )  ______P ( | ​H 1 ) 
​.​
In other words, this is the factor with which we have to mul-
tiply the prior odds to obtain the posterior odds.​
In practice, if the two hypotheses represent restrictions 
on a – not necessarily one-dimensional – parameter  θ​,​ i.e. 
 H 0​ : θ ∈  θ 0  and   H 1​ : θ ∈  θ 1 ( θ 0​∩​​θ 1 = ∅ ) then we have 
 B  F 01 =  
 ∫ 
ϑ∈ θ 0 
 P ( | ​H 0 , ϑ) π (ϑ | ​H 0 ) ϑ  _________________ ∫ 
ϑ∈ θ 1 
 P (| ​H 1 , ϑ) π (ϑ | ​H 1 ) ϑ
 
where  π (ϑ)​ is​ the​ prior​ distribution​ of​ the​ parameter.​This​ is​




This​definition​can​be​ substantially​ simplified​ in​ the​prac-
tically​ very​ important​ scenario​ of​ the​ null​ hypothesis​ being​
a​point​null​ (i.e.​ ​θ =  (ξ, η)​,​where​ ​dim ξ = 1 with  H 0​ : ξ =  ξ 0 
and   H 1​ : ξ​ ≠​ ​ξ 0 ,  thus  η​ represents​ the​ nuisance​ parameters).​
If we assume that the prior for  ξ is continuous at  ξ 0 (condi-
tional on the nuisance parameters) then the numerator can 
be​ written​ as​ ​∫ P ( | ξ =  ξ 0 ,  H 1 , η)​ π (η | ξ =  ξ 0 ,  H 1 ) dη instead of 
​∫ P ( | ​H 0 , η) π (η | ​H 0 ) dη​.​ However,​ ​∫ P ( | ξ =  ξ 0 ,  H 1 , η) π (η | ξ = 
ξ 0 ,  H 1 ) dη = P ( | ξ =  ξ 0 ,  H 1 )​,​ and​by​Bayes’​ theorem​we​have 
  P ( | ξ =  ξ 0 ,  H 1 ) =  
P (ξ =  ξ 0​ | ​H 1 , ) P ( | ​H 1 )   _________________ P (ξ =  ξ 0​ | ​H 1 ) 
​ ​.​As​the​denominator​is 
 P ( | ​H 1 )​(see​Eq.​(5)),​the​Bayes​Factor​is​simply
 B  F 01 =  




mation​ on​ the​ investigated​ parameter’s​ distribution.​ This​ is​








is​no​ longer​ a​ ”context​ independent”​measure,​ but​ rather​ the​
prior​belief​is​needed​to​be​incorporated​later​on​(which​is​just​
an​advantage,​i.e.​that​Bayes​Factors​make​this​fact​explicit).​
As​ Bayes​ Factor​ has​ many​ further​ advantages,​ and​ cor-
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wider​ application​ been​ endorsed​ by​ Goodman​ [31,​ 32]​ and​
Wagenmakers​[33],​among​others.​
Despite​ this,​ Bayes​ Factors​ are​ seldom​ used​ in​ practice​
in​ medicine,​ especially​ in​ ”ordinary”​ clinical​ papers​ –​ their​
appearance​is​mostly​limited​to​papers​that​specifically​demon-
strate​or​investigate​their​usefulness​(e.g.​[34]),​but​they​almost​




them​to​ that​of​null​hypothesis​significance​ testing​ in​a​sim-
ple,​but​realistic​medical​scenario​on​individual​patient​data.​
The​paperwill​be​purely​descriptive,​ i.e.​no​ in-depth​attempt​
is made to give theoretical (mathematical) explanation to the 
observed​phenomena.
2 Material and Methods
2.1 Investigated questions
The​ aim​ will​ be​ to​ investigate​ the​ applicability​ of​ Bayes​











this​question​can​be​addressed​by​the​​t -test, as discussed in any 
standard​textbook​[35,​36].​The​Bayes​Factors​approach​in​its​
most​ popular​ form​ for​ this​ case​ [37,​ 38]​will​ be​now​briefly​
outlined.​
Consider the following regression model: 
 y i = α +  β 1  x i,1 +  β 2  x i,2 + … +  β p  x i,p +  ε i , 
where  ε i​is​assumed​to​be​independent​normal​variate​with​zero​
mean and constant  σ​ variance.​Our​ research​ question​ can​ be​
formulated as  H 0​ : ​β j = 0 versus  H 1​ : ​β j​ ≠​ 0​,​ therefore​by​6​we​
have 
 B  F 01 =  
 ∏ i=1 n ϕ (  y i​−​​(α +  β 1  x i,1 … +  β j−1  x j−1,i +  β j−1  x j+1,i + … +  β p  x i,p )     _______________________________σ )     _________________________________________    
 ∫ b  ∏ i=1 n ϕ (  y i​−​​(α +  β 1  x i,1 … +  β j−1  x j−1,i + b  x j,i +  β j−1  x j+1,i + … +  β p  x i,p )     ___________________________________σ ) π (b) b
 , 
where  ϕ​ is​ the​ standard​ normal​ density.​Assuming​we​ know​
every​ regression​ coefficient​ apart​ from​ ​β j and the error vari-
ance  σ​(these​assumptions​can​be​relaxed,​or​we​can​consider​
the​ analysis​ to​ be​ conditional​ on​ them)​ all​we​ need​ is​pi(b), 
the​ prior​ distribution​ of​ a​ regression​ coefficient.​ The​ most 
popular​choice​is​Cauchy-distribution,​which​is​equivalent​to​a​
hierarchical​normal/inverse​gamma​model​ (but​ this​ latter​can​
be​more​easily​generalized​to​this​multivariate​case):​
 β | g ∼ N (0, g  σ 2  ( X T X / n) −1 ) 
 g ∼ InvGamma (1 / 2,​​s 2​ / 2) , 
where  β =  [ β i ] i=1 
p ,  X =  [ x i,j ] i=1,j=1 
n,p  and  s is a new (hyper) 
parameter.​This​ choice​ is​ usually​ called​weekly​ informative,​




Now that the methods are clarifed, the questions of interest 
will​be​more​specifically:​
•​ How​Bayes​Factors​compare​to​​p -values? 
•​ How​is​ this​relationship​affected​by​certain​parameters,​
particularly the applied prior ( s​)​and​the​sample​size?
2.2 Patient data








(although sometimes varying from cycle to cycle), including 
demographic data, physical examination, collection of clinical 
chemistry parameters, and a thorough questionnaire concentrat-
ing​on​anamnesis​and​lifestyle.​Now​​p = 43 clinical chemistry 
parameters1​from​the​2013/14​cycle​–​the​most​recent​available​
–​will​be​used​[41].​To​make​the​database​more​homogeneous,​
it​was​ filtered​ to​males​ aged​ 18​ years​ or​more.​ For​ simplic-
ity,​ subjects​with​ any​missing​ value​were​ left​ out.​Although​
for​precise​analyses​it​is​important​to​take​the​survey​structure​












Triglycerides), TCHOL (cholesterol – total), CBC​ (Complete​Blood​Count​with​
5-part​Differential​–​Whole​Blood),​GHB​(Glycohemoglobin),​INS​(Insulin),​GLU 
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2.3 Programs used
All analysis was carried out under the R statistical program 
package,​ version​ 3.3.1​ [42]​ with​ a​ custom​ script​ developed​
for​ this​purpose​ that​ is​ available​ at​ the​ corresponding​ author​
on​ request.​The​Bayes​Factors​were​ calculated​with​ package​
BayesFactor,​ version​ 0.9.12-2​ [43].​ Data​ visualization​ is​
performed with the lattice​package,​version​0.20-33​[44].
3 Results




rithm of the  p​-value​and​the​Bayes​Factor.​This​is​no​exception:​
Fig.​2​shows​the​same​scatterplots​for​all​variables​(all​variable​
selected​ as​ response,​ one​ at​ a​ time,​ and​ the​ remaning​ being​
predictors)​in​logaritmic​scale.​Indeed,​even​the​smallest​linear​
correlation​coefficient​between​the​logarithms​is​over​​0.99​.​
Next,​ the​role​of​ the​sample​size​will​be​ investigated.​The​
same​analysis​as​on​Fig.​1​was​repeated,​but​with​smaller​sam-
ples.​These​were​randomly​sampled​from​the​whole​database​
(with​ replacement);​ sample​ sizes​50,​ 100,​ 200​ and​500​were​
used.​Actually,​ the​ aim​ of​ this​ investigation​ is​ twofold:​ this​
method​makes​it​possible​not​only​to​investigate​the​effect​of​
sample​size,​but​also​the​sampling​variation​as​now​many​sam-













the strong relationship in this sense too, and – more importantly – 
it​is​now​apparent​that​this​gets​stronger​withsample​size.
Finally,​ the​ effect​ of​ the​ used​ prior​ was​ investigated.​As​
it​was​ already​ discussed,​ ”used​ prior”​ now​means​ the​ selec-
tion of the  s​ hyperparameter;​ in​ addition​ to​ the​default​ ​√ 
__
​2  / 4​






the points shifted upwards as the value of  s​ increases;​ this​ is​
again​logical.
4 Discussion and conclusion
 p​-values​and​Bayes​Factors​are​strongly​related.​Their​rela-
tionship comes as no surprise as they measure related charac-
teristics;​the​strength​of​the​connection​is​what​can​be​surpris-
ing​at​first​glance.​
However,​ it​ should​ be​ noted​ that​ in​ simple​ cases​ it​might​






-value is related to the posterior density, and they are changing 



































































































(a) Linear scale (b)​Logarithmic​scale
Fig. 1  p​-values​and​Bayes​Factors​of​the​explanatory​variables​in​the​regression​of​glycohemoglobin.
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(a)   p -value (b)​Bayes​Factor
Fig. 3​Effect​of​sample​size​–​shown​in​the​panel​titles​–​and​sampling​variation​on​​p​-values​and​Bayes​Factors​(univariately),​with​the​glycohemoglobin​being​the​
response​variable​and​serum​glucose​being​the​investigated​predictor​variable;​vertical​black​lines​indicates​the​estimates​for​the​full​sample​(logarithmic​scale).
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The​present​research​also​makes​it​clear​that​–​in​the​inves-
tigated scenario – the relationship gets stronger with increasing 
sample​size:​for​samples​larger​than​a​few​hundred​observation,​
the​relationship​is​almost​perfect.​
When​using​JZS​prior,​the​choice​of​the​​s parameter had no 
major​impact​on​the​relationship​between​​p​-values​and​Bayes​
Factors,​but​uniformly​shifted​Bayes​factors.​
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Fig. 5 Effect of the choice of prior on  p​-values​and​Bayes​Factors,​with​the​
glycohemoglobin​being​the​response​variable​(logarithmic​scale).
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